ArticleTherapeutic advances in drug safety2026
Development and validation of a MedDRA-based signal detection construct for drug-induced neurobehavioral impairment.
Article in Therapeutic advances in drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The FDA's Guidance for an industry evaluating drug effects on the ability to operate a motor vehicle describes the need to evaluate drug-induced neurobehavioral impairment. However, the guidance does not provide instruction or the means to implement the analysis. Objective: The proposed Construct provides a means to operationalize the evaluation of adverse event datasets for this disorder. Design: A noninterventional pharmacoepidemiologic methods development study using routinely collected health data. Methods: Preferred terms for the Construct were derived by mapping the domains of concern cited by the Guidance to the corresponding MedDRA terms. Additional terms were derived from the MedDRA preferred terms cited in the warning section of labels from drugs with a warning about driving or operating machinery. The performance of the Construct was evaluated by comparing adverse events for the FDA Adverse Event Reporting System (FAERS) database for drugs considered to be of high risk versus low risk for this condition using descriptive statistics and a nonparametric test. Results: A Construct of PTs (neurobehavioral impairment term list; NITL) was obtained after identification of 55 drugs with the Warning in their FDA-approved label for driving or operating machinery based on drug-induced neurobehavioral impairment. Additional terms not covered in the labels were derived from the five domains of interest cited in the Guidance for a total of 52 PTs. Comparison of the difference in the proportion of FAERS reports with the NITL terms in drugs with and without the relevant labeling was nominally significant ( Conclusion: A MedDRA-based Construct was generated for the selection of adverse events related to drug-induced neurobehavioral impairment. The Construct discriminated high- from low-risk drugs based on publicly available adverse event profiles. Further evaluation with clinical trial data will be needed to facilitate its use for signal detection in safety analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.